

EUROPEAN SOCIETY OF CARDIOLOGY
Dedicated to improving the quality of life in the European population
by reducing the impact of cardiovascular disease

Re: Annual Scientific Report of the Working Group 18: Thrombosis

To: Mrs Wilma Thieme,
Executive Secretary
ESC Board
Tel. # 31. 186 614 145
Fax # 31. 186 614 258
E-mail : wilmathieme@planet.nl
E-mail : wilmathieme@chello.nl(See file: letter WG annual report2003.doc)

August 15th 2003

-Introduction

This is the first report that I file to the ESC as Chairman of the Working Group 18 ("Thrombosis"), since when I had the honour and the responsibility of the Chairmanship received from Prof. Raffaele de Caterina in the year 2002. Dr Steen Kristensen was also appointed new Co-Chairperson, and he will take over the Chairmanship at the time of the ESC Congress in Munich, September 2004.

The Nucleus of the WG currently consists of the following persons:

- Lina Badimon, Chairman
- Steen Dalby Kristensen, Co-Chairman
- Raffaele De Caterina Past-Chairman
- Kurt Huber, Treasurer
- Gilles Montalescot,
- Keith Fox
- Freek WA Verheugt.

The Nucleus has met the last time in Florence on June 7th,2003. The current status of the WG activities, as summarized in the report of that meeting, is hereby reported.

1- Statement of the objectives of your Working Group

- 1.1. To enhance knowledge of thrombosis in clinical cardiology in Europe.
- 1.2. to stimulate postgraduate education in thrombosis both at the European Congress of Cardiology and beyond.
- 1.3. to stimulate clinical research in thrombosis in clinical cardiology in Europe, to be performed preferably by young investigators.
- 1.4. to stimulate basic research on thrombosis in order to increase our knowledge on the pathophysiology to initiate the development of new preventive and therapeutic tools

2- Number of sessions organised at the ESC Annual Congress

There will be this year an important number of Sessions organised by the WG on Thrombosis, two Symposiums and two Clinical seminars. Other proposals coming from our WG have been taken by the Basic Science Track Programme. Below find the activities for Vienna 2003:

Meeting and Functions	Day/ Time / Location		
Working Group Meeting	August/30th,	14:00-15:00,	Wenckebach (Hall 12)
Bussiness Meeting (entire WG)	September/1 st	12:45-13:45,	Paris (Blue Zone)
Symposium	August/31 st	11:00 -12:30	Prague (Red Zone)
Tissue factor : a key player for thrombosis and inflammation			
Clinical Seminar	August/31 st	16:30-18:00	Belgrade (Red Zone)
New therapeutic tools in atherothrombosis			
Symposium	September/1 st	14:0 -15:30	Athens (Blue Zone)
Update in platelets: from signalling to function			
Clinical Seminar	Sept/2 nd ,	08:30-10:00	Warsaw (Red Zone)
Anticoagulation during and after acute coronary syndromes			
YIA-Thrombosis Session	August/31 st	12.40-13-55	Basel (Blue Zone)
Basic Science Meeting with President	Sept/3 rd	8:30-10:00	ESC-VIP meeting Room Hall 12-Congress Center
WG-Get Together Cocktail	Sept/2 nd	19:30	Snack Restaurant HALL 14- Congress Center
WG-Nucleous Dinner	Sept/03	19:30	Restaurant GRIECHENBEISL Mark Twain Room Am Fleischmark 11 A-1010 Vienna

3. Activities run outside the ESC Annual Congress

3.1. Atherothrombosis 2003: A meeting of the Working Group on Thrombosis of the European Society of Cardiology

The second Congress of the Working Group, was held in Florence June 6-7th, 2003, at the Grand Hotel Baglioni.

Scientific Organizers: Raffaella de Caterina and Lina Badimon.

Because it was organized in Italy the meeting was endorsed by the following Italian National Scientific Organizations :

- Gruppo di Lavoro Trombosi, Aterosclerosi e Biologia Cardiovascolare-Societa Italiana di Cardiologia,
- Societa Italiana per lo Studio della Emostasi e della Trombosi, and
- Societa Italiana per lo Studio dell'Aterosclerosi.

The programme focussed on the pathophysiology of atherosclerosis and thrombosis as the basis for rational intervention. The meeting was targeted to cardiologists (max 125) belonging to the Working Group from all over Europe. The faculty came from Europe (21 speakers) and the United States (6 speakers).

The meeting was highly rated by speakers and audience. Approximately 100 delegates attended the meeting. Our intention was to organize a kind of scientific forum to stimulate questioning and comments of the audience to the presentations and the free discussions. This end was successfully reached as discussions were very rich and interactive.

Regarding sponsorship the last page of the programme shows the sponsors. Additional sponsorship came from the resources of the Working Group. The final budget has not been presented to me as yet since it is presently being closed by the Organizing Secretariat Regia Congressi. Below the digital version of the programme is included.

3.2 Course Antithrombotic Therapy Update 2003

16-18, October, 2003, Nice.

ESC-Heart House

Dates have been set for the fifth course of the series, again organized at the European Heart House by Steen Dalby Kristensen and Raffaele De Caterina.

A preliminary programme has been laid down. Main changes as to previous courses, addressed to increase the audience, will be a greater representation of the Working Group, the suggestion that each member of the faculty will indicate at least five junior colleagues from his/her country for participation in the course and the need to provide funding for these participations. In addition, the need that the entire faculty remains on site for the entire duration of the course (rather than "touch and go") has been stressed and agreed upon. Further improvement will be the production of a CD-ROM with slide presentations and pertinent literature. The Course is another important opportunity in the quest for sponsorship. Local branches of supporting companies may support the participation of younger doctors. The importance of having a goal of at least 50 enrolled participants has been stressed.

3.4 Fellowships and Awards.

The WG wants to continue the initiative of the Young Investigator Award on Thrombosis. The Fellowships in Coronary Thrombosis were stopped because of the ending of the Merck funding and the absence of ensuing additional sponsors. Also it was felt opportune that fundraising for the year might be better concentrated to the Congress and the Course organization (see above).

3.5. Meeting of the WG Nucleus and of the entire WG in Vienna 2003 and Social events in Vienna 2003,

Cocktail reception for the entire WG and the Nucleus Dinner.

The organization of Social events have continued a tradition initiated years ago because they are considered extremely important to reinforce the links with members of the Working Group and with Partner Industries.

3.6 The History of the Working Group on Thrombosis: initiative

Raffaele De Caterina has compiled a list with names and addresses of previous Chairmen of the WG and will try to have, at least for the past 12 years, a collection of "highlights from the Working Group Chairmen" each related to his/her own mandate. This will establish some historical track on the activities of the WG.

3.7 Cooperation with the construction of the new ESC website for WGs Nucleus Web Site

Dr. Kurt Huber started organizing a Web Site for our WG. He got in contact with the ESC webteam and was informed that we had to wait until the ESC was more advanced in the general procedures, until about April 2003. Between October 2002 and January 2003 he was twice at the Heart House to work in this issue.

At the moment we stand on:

- definition of the current objectives of our WG (see above)
- updating of the member list
- listing of the activities of our WG not already published in the old version of the website

4. Membership

The current situation as of today is 165 members, with the addition of 13 new members since last year.

5. Registries and Surveys

None in progress.

6. Study Groups

6.1 Task Force on Pre-hospital reperfusion therapy in STEMI

Dr. Kurt Huber, on behalf of the WG submitted a grant proposal to the ESC for the establishment of a Task Force on "Improvement of guidelines for diagnosis and therapy of ST-elevation myocardial infarction (STEMI) in the prehospital setting" that was granted.

Dr Huber has completed a preliminary paper on this topic which he will present at the nucleus meeting in Vienna. The paper should be distributed among the WG-Nucleous members and other invited potential co-authors and a final decisive meeting should take place in autumn gathering all the co-authors to reach and final document. For this meeting we will use the sponsorship by the ESC in the amount of 5,000 Euros.

7. Financial Situation.

We have had an excellent financial situation in the last years as mostly related to the extremely successful fundraising campaign of Dr. Fitzgerald. The current Working Group budget, including the handling of the funds for the Postdoctoral Research Fellowship in Coronary Thrombosis and the Young Investigator Award, is reported in the next part of this report.

The last information received by the Treasurer, Dr. Huber, from Barbara Lefevre is from April 23, 2003. At that time the WG had a positive budget with • 119.637,42 Euros.

.In addition we have received sponsor money in the amount of • 24.291,00 Euros for our educational course in October 2003.

So in total we had • 143.928.42. Euros.

See enclosed statement from ESC-Financial Office.

Unfortunately, we have not closed as yet the Atherothrombosis meeting, and we may have to spent the 30,000 Euros as agreed by the WG to sponsor the event (if needed).



Prof. Lina Badimon
Chairman

GENERAL INFORMATION

CONGRESS VENUE

Grand Hotel Baglioni
Piazza Unità Italiana, 6
50123 - Florence (Italy)
Ph: + 39 055 23580
Fax: + 39 055 2358895

SCIENTIFIC SECRETARIAT

Prof. Raffaele De Caterina
University Cardiology Division
"G. D'Annunzio" University
Chieti, Italy
Ph: +39 0871 41512
Fax: +39 0871 402817
rdcaterina@unich.it

Prof. Lina Badimon
Cardiovascular Research Center
ICCC-CSIC
Hospital Santa Creu y Sant Pau
Barcelona, Spain
Ph: +34 934006146
Fax: +34 932045904
lbadim@iccc.csic.es

ORGANIZING SECRETARIAT

Regia Congressi
Via Pietro Dazzi, 12/14
50141 - Florence (Italy)
Ph: + 39 055 436531
Fax: + 39 055 436540
e-mail: info@regiacongressi.it

The organizers express gratitude
to the following sponsors:



A Meeting of the Working Group on Thrombosis
of the European Society of Cardiology
Raffaele De Caterina and Lina Badimon, Organizers
Mario Mariani and Gian Franco Gensini, Presidents

Atherothrombosis 2003

Also endorsed by:
Gruppo di Lavoro Trombosi, Aterosclerosi e
Biologia Cardiovascolare -
Società Italiana di Cardiologia -
Società Italiana per lo Studio della Emostasi e della Trombosi
Società Italiana per lo Studio dell'Aterosclerosi

Florence, June 6-7, 2003
Grand Hotel Baglioni

PROGRAMME

Faculty:

Rosanna Abbate (Florence, Italy)
Piero Arversà (Valhalla, USA)
Lina Badimon (Barcelona, Spain)
Robin Choudhury (Oxford, UK)
Raffaele De Caterina (Chieti, Italy)
Desmond Fitzgerald (Dublin, Ireland)
Christian Gachet (Strasbourg, France)
Gian Franco Gensini (Florence, Italy)
Michael A. Gimbrone (Boston, USA)
Peter Grant (Leeds, UK)
Goran K. Hansson (Stockholm, Sweden)
Kurt Huber (Wien, Austria)
Steen Dalby Kristensen (Aarhus, Denmark)
Ulrich Landmesser (Hannover, Germany)
Mario Mariani (Pisa, Italy)
John F. Martin (London, UK)
Philippe Meuwinkel (Paris, France)
David Moliterno (Cleveland, USA)
Gilles Montalescot (Paris, France)
Yale Nemerus (New York, USA)
Andrew C. Newby (Bristol, UK)
Rodolfo Paoletti (Milan, Italy)
Carlo Patrono (Rome, Italy)
Jorge Platzky (Boston, USA)
Steven Steinhuß (Chapel Hill, USA)
Freek W.A. Verheugt (Nijmegen, The Netherlands)
Lars Wallentin (Uppsala, Sweden)

PROGRAMME

Day 1 - June 6 - Friday

Basic pathophysiology of atherosclerosis
Chair: L. Badimon, G.F. Gensini

- 9:00 *Biochemical Factors, Endothelial Gene Expression and Atherogenesis*
Michael A. Gimbrone Jr, Boston, USA
- 9:30 *Oxidative stress as a general inducer of cardiovascular risk*
Ulrich Landmesser, Hannover, Germany
- 10:00 *Mechanisms of atherogenesis in Diabetes*
Raffaele De Caterina, Chieti, Italy
- 10:30 *Coffee break*

Chair: R. De Caterina, M. Mariani

- 11:00 *Tissue factor: regulation of expression and biological action*
Yale Nemerus, New York, USA
- 11:30 *Vascular and systemic inflammation, infections, immunity and vascular disease*
Goran K. Hansson, Stockholm, Sweden
- 12:00 *Animal models of plaque instability and the role of metalloproteinases*
Andrew C. Newby, Bristol, UK
- 12:30 *PPAR α and vascular disease*
Jorge Platzky, Boston, USA

1:00 *Lunch*

Basic pathophysiology of thrombosis
Chair: D. Moliterno, R. Abbate

- 14:00 *Thrombotic events in atherosclerosis. Role of fibrinogen*
Lina Badimon, Barcelona, Spain
- 16:30 *The role of the platelet P2 receptors in atherosclerosis*
Christian Gachet, Strasbourg, France
- 17:00 *Pharmacogenetics of GP IIb/IIIa antagonism*
Desmond Fitzgerald, Dublin, Ireland
- 17:30 *End of Session*

Day 2 - June 7 - Saturday

Pharmacology and Therapy: understanding and interpreting clinical results through knowledge of basic mechanisms
Chair: K. Huber, S. D. Kristensen

- 09:00 *The vulnerable plaque - Insights from imaging techniques*
Robin Choudhury, Oxford, UK
- 09:30 *Aspirin, drug interactions and aspirin "resistance"*
Carlo Patrono, Rome, Italy
- 10:00 *Lessons from glycoprotein IIb/IIIa antagonists with or without catheters*
David Moliterno, Cleveland, USA
- 10:30 *Glycoprotein IIb/IIIa receptor antagonists: current status and perspectives*
Steven Steinhuß, Chapel Hill, USA
- 11:00 *Coffee break*
- Chair: J. F. Martin, C. Patrono
- 11:30 *Low molecular weight heparins and protenase-3*
Gilles Montalescot, Paris, France
- 12:00 *Thrombotic inhibition - New anti-thrombotics*
Lars Wallentin, Uppsala, Sweden
- 12:30 *Status and protection of coronary disease and stroke*
Rodolfo Paoletti, Milan, Italy
- 13:30 *UK and new oral anticoagulants in ischemic heart disease*
Freek W.A. Verheugt, Nijmegen, The Netherlands
- 13:30 *Lunch*

Perspectives
Chair: E. Badimon, R. De Caterina

- 14:00 *Pharmacogenetics and Pharmacogenomics*
Peter Grant, Leeds, UK
- 16:30 *Mending a damaged heart: stem cells in cardiology*
Piero Arversà, Valhalla, USA
- 17:00 *Cellular cardiomyoplasty*
Philippe Meuwinkel, Paris, France
- 17:30 *Cardiovascular gene therapy: is there still chance for success?*
John F. Martin, London, UK
- 18:00 *Drug-eluting stents in brachytherapy for restenosis: Have we solved the problem?*
Steen Dalby Kristensen, Aarhus, Denmark
- 18:30 *Closing remarks*